UCLA Center for Biological Radioprotectors

加州大学洛杉矶分校生物辐射防护中心

• 批准号: 7025501
• 负责人: WILLIAM H. MCBRIDE
• 金额: $ 284.32万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-31 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7025501
• 关键词: clinical research; cooperative study; drug discovery /isolation; radiobiology; radioprotective agents

In spite of the long history of achievements in the study of the critical effects of radiation on normal tissues in vitro and in vivo, there is a dearth of agents immediately available for prophylaxis, mitigation and treatment of radiation injury, a lack of high throughput methods to assess efficacy, an absence of biodosimetry devices to identify individuals who need treatment, and a shortfall in the number of personnel appropriately trained to advance these fields. The goal of the UCLA-CMCR is to develop a drug discovery, evaluation, and development infrastructure that can identify novel agents and test them, alongside agents of known potential, for their ability to ameliorate the effects of radiation on normal tissue damage. Their potential to enhance radio-carcinogenesis will also be assessed, since this is an important aspect of radiation exposure. Multiple high and low throughput screening assays will be performed that will allow compounds to be selected for further characterization by LTS assays. One concept that will be explored is that molecular "signatures" can be used to classify modulators of radiation responses and can be exploited for rational development of effective agents. After further selection, compounds will be tested in vivo for efficacy and toxicity and, if successful, will be entered into as product development plan. The ordered evaluation of agents within one center is the optimum way of speeding up product development for validation, licensing, and inclusion of products in the Strategic National Stockpile. The UCLA CMCR will have a lean structure but a broad focus. It integrates harnesses multiple strengths at UCLA to the CMCR Program and builds a rich environment for research, training, and product development in radiation sciences. Other members of the CMCR network, groups and individuals in academic and commercial entities will evaluate agents in our model systems and we will utilize other CMCRs to test our compounds for efficacy in their systems. In this way it will link to industry and to the CMCR Program as a whole.

尽管在研究辐射对体外和体内正常组织的关键作用的研究中的成就悠久，但缺乏预防，缓解和治疗辐射损伤的药物，缺乏高吞吐量方法为了评估功效，缺乏生物测量设备来识别需要治疗的人，以及经过适当培训以推进这些领域的人员人数短缺。 UCLA-CMCR的目的是开发一种药物发现，评估和开发基础设施，该基础设施可以鉴定出新颖的药物并与已知潜力的药物一起测试它们，以减轻辐射对正常组织损伤的影响。它们增强无线电癌发生的潜力也将被评估，因为这是辐射暴露的重要方面。将执行多个高和低吞吐量筛选测定法，以通过LTS分析选择化合物以进一步表征化合物。将要探讨的一个概念是，分子“签名”可用于对辐射反应的调节剂进行分类，并可以利用有效剂的合理发展。经过进一步的选择，将在体内对化合物的疗效和毒性进行测试，如果成功，将作为产品开发计划进入。对一个中心内代理商的有序评估是加速产品开发以验证，许可和将产品纳入战略国家库存中的最佳方式。 UCLA CMCR将具有精益的结构，但重点很广。它将在UCLA的多个优势集成到CMCR计划，并为辐射科学的研究，培训和产品开发建立了丰富的环境。 CMCR网络的其他成员，学术和商业实体中的团体和个人将评估我们的模型系统中的代理，我们将利用其他CMCR测试我们的系统中功效的化合物。这样，它将与行业和整个CMCR计划链接。